Purchase Order 75N91019P00720

<p>The National Institutes of Health Clinical Center awarded a purchase order to Centre International de Recherche sur le Cancer (IARC) for $22,124.00 on April 23, 2020, for germline DNA samples and data from renal cell carcinoma patients. Performance occurs in France with an ultimate completion date of April 30, 2021. The order is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Health Research, Inc. (Roswell Park Division) valued at $16,380.00 on June 4, 2019, for germline DNA samples and data from renal cell carcinoma patients to support the NCI's Renal Cell Carcinoma Genome-Wide Association Study. Work is performed in Buffalo, New York. The order carries a firm fixed price structure and a completion date of December 3, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to the University of Southern California for $11,633.45 on August 1, 2014, to perform MethyLight amplification and detection of selected CpG dinucleotides in six pre-selected DNA sequences from bisulfite DNA samples prepared from 144 DNA samples from melanoma-prone families. Work is performed in Los Angeles, California. The order carries a firm fixed-price structure with an ultimate completion date of July 31, 2015.</p>

<p>The National Cancer Institute awarded a purchase order to Kaiser Foundation Hospitals for $49,870 on September 29, 2020, to provide services from Kaiser Permanente Washington Health Research Institute informing the feasibility of a larger tissue retrieval effort for patients within the Kaiser Breast Cancer Survivors' Cohort Study. Work is performed in Oakland, California. The order is firm fixed-price with an ultimate completion date of March 28, 2021.</p>

<p>The National Cancer Institute issued a $25,116.81 delivery order to Illumina, Inc. on August 31, 2020, for reagents and consumables, with final completion on September 30, 2020.</p> <p>Place of performance is San Diego, CA 92122. The order is firm fixed price with no set-aside designation. The source does not identify the parent vehicle under which this delivery order was issued.</p>

<p>The National Cancer Institute awarded a purchase order to Advanced Cell Diagnostics, Inc. for laboratory testing with a ceiling value of $19,772.00 and an award date of August 13, 2020. The order carries no set-aside designation and firm fixed pricing. Work is performed in Newark, California. The purchase order has an ultimate completion date of September 30, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Advanced Cell Diagnostics, Inc. for laboratory and testing services valued at $12,345.00, effective August 6, 2020. Performance will take place in Newark, California, with ultimate completion by September 4, 2020. The order carries firm fixed pricing and no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Advanced Cell Diagnostics, Inc. valued at $13,814.40 on September 17, 2020, with completion targeted for November 26, 2020. The order carries firm fixed pricing with no small business set-aside. Performance occurs in Newark, California. The purchase order procures RNA detection technologies and related diagnostic products from Advanced Cell Diagnostics' RNAscope platform for cancer research support.</p>

<p>The National Cancer Institute issued a $105,365.88 delivery order to Illumina, Inc. on August 5, 2020, for reagents and consumables.</p> <p>Place of performance is San Diego, CA 92122. Ultimate completion date is September 4, 2020. The order is priced on a firm fixed-price basis with no set-aside applied.</p>

The National Cancer Institute awarded a purchase order to ECOG-ACRIN Medical Research Foundation, Inc. for digital transfer of clinical data and histological slide images, valued at $21,660.69, with an award date of June 15, 2026. Performance is located in Bethesda, Maryland. The order requires application of molecular prediction models to digitized histopathology slides from 1,154 clear cell kidney cancer patients, delivery of path-omic analysis and clinical correlation of the entire patient...